LOBBYIST

Alanna Temme

221ACTIVITIES

2ORGS REPRESENTED

12BILLS

Revolving door — covered positions

Federal positions Alanna held before / during the 2-year LDA window. This is the credibility signal — who they were inside the building before they started lobbying it.

Legislative Director, U.S. Representative Jon Porter

Organizations represented

Orgs whose LD-2 filings list Alanna as an active lobbyist, sorted by activity volume.

Lmh Strategic Solutions219 activities Pharmaceutical Research and Manufacturers of America (PhRMA)2 activities

Bills they file on

H.R. 94618 mentions

H.R. 221316 mentions

H.R. 149216 mentions

S. 83216 mentions

H.R. 167212 mentions

S. 186212 mentions

H.R. 126212 mentions

S. 93212 mentions

H.R. 46926 mentions

S. 5746 mentions

S. 23556 mentions

H.R. 16916 mentions

Topics in Filings

Policy topics Alanna files on across all their LD-2 activities.

Healthcare-related legislative and regulatory issues×78

Impacting the biotechnology, pharmaceutical, and consumer health industry×72

General health care coverage and reimbursement for prescription drugs×72

Drug pricing reform×48

Food and Drug Administration legislative and regulatory issues×48

Pharmaceutical Supply Chain×35

General Medicare and Medicaid Issues×25

Prescription drug payment reform×19

Medical Supply Chain Resiliency Act×16

Maintaining Investments in New Innovation×12

Pediatric Review Reauthorization×12

Medicare/Medicaid issues×6

Show all 41 topics (+29 more) ▾

Medicaid drug rebate program×6

Prescription drug pricing, including MDRP Substance Use Disorder Policy×6

ORPHAN Cures Act×6

Provide strategic counsel and advocate on issues×6

Inc. specifically×6

Prescription Drug Competition Issues×6

Increasing Prescription Drug Competition Act×6

VA Appropriations Request×6

Fiduciary PBM×6

Lower Costs×6

More Transparency Act×6

HSA Provisions×6

Patients Deserve Price Tags Act×6

General health care coverage issues×6

Healthcare reform×6

Reimbursement issues×6

Vaccine Access×6

Access to and reimbursement of medical devices in Medicare program×6

Health programs impacting MDMA×6

Barriers to market access for medical device companies×6

Supply chain issues×6

Cyber security issues×6

TCET Issues×6

Inflation Reduction Act×6

Give Kids a Chance Act×6

Monitored Most-Favored Nation×6

Drug Pricing and Access×1

Pharmacy Benefit Managers×1

Medicaid State-Directed Payments and Intergovernmental Transfers×1

Issue mix

LDA general-issue codes weighted by activity count.

Pharmacy89

Health Issues78

Medicare/Medicaid38

Trade (domestic/foreign)16